ZURA (29) TRXB (49) IRLA (32) FENC (36) ⌘ Pro Terminal →

Kyverna Therapeutics Inc. (KYTX) — RQD Stock Rating Cockpit

$5.85 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.83

Kyverna Therapeutics Inc. (KYTX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $361.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.83 (-0.31%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KYTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY KYTX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 40.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$6.39-11.3% Next Q

Q2 (-2Q)

Grade D$5.67-4.9% Next Q

Q3 (-1Q)

Grade D$5.39+8.5% Next Q

Current

Grade D-$5.85-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KYTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KYTX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.91) and Max Pain ($6.14) forces dealer call-delta covering toward $14.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KYTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KYTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

40.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE8% OF RANGE

L: $5$5.85H: $14

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on KYTX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

13/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like KYTX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYTX)

✓Walkthrough of KYTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KYTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.52%▼ DESCENDING CHANNEL

2026-10-30O $5.74H $5.87L $5.55C $5.85VOL 640.1K

RES: $7.19SUP: $5.07SMA50: $6.91SMA200: $8.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYTX Butterfly Map → + Track KYTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KYTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KYTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYTX)

Health Care Rank #573 of 1016 ⚔️ ZURA vs KYTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KYTX vs. ZURA, TRXB, IRLA, FENC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kyverna Therapeutics Inc. (KYTX) ranks #573 by composite RQD confidence (42/100, grade D-) and #497 by equity capitalization ($361.8M). Within this direct 5-issuer industry benchmark cohort, KYTX leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with KYTX at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KYTX ACTIVE Kyverna Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.68%	$361.8M	Benchmark Subject
ZURA Zura Bio Limited (Class A)	E	29/100	—	—	-35.0%	-11.49%	$370.9M	/zura-vs-kytx →
TRXB TRex Bio Inc.	D	49/100	—	—	—	-6.31%	$371.1M	/trxb-vs-kytx →
IRLA IRulya Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.05%	$342.8M	/irla-vs-kytx →
FENC Fennec Pharmaceuticals Inc.	D-	36/100	—	—	-25.9%	+0.74%	$383.6M	/fenc-vs-kytx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001994702

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kyverna Therapeutics Inc. (KYTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$161.3M, operating cash flow of -$153.7M, and free cash flow of -$153.7M (-32.0% YoY). On the balance sheet, KYTX closed FY2025 with $293.8M in total assets against $24.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$161.3M	-$153.7M	-$153.7M	$293.8M	$24.7M
FY2024 (FY)	2024-12-31	$0	-$127.5M	-$114.3M	-$116.5M	$304.6M	—
FY2023 (FY)	2023-12-31	$0	-$60.4M	-$52.4M	-$52.4M	—	—

3. KYTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kyverna Therapeutics Inc. (NASDAQ: KYTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $5.85 (-0.68% 1D, market cap $361.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KYTX ranks #573 in composite RQD confidence.

How does KYTX compare to ZURA and TRXB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KYTX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M) and TRXB (TRex Bio Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $371.1M). Among the 5-stock peer group, KYTX leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KYTX?

Per KYTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001994702), Kyverna Therapeutics Inc. generated $0 in revenue, -$161.3M in net income, and -$153.7M in free cash flow against $293.8M in total assets and $24.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KYTX trading relative to its 50-day, 200-day, and 52-week technical levels?

KYTX last traded at $5.85 (-0.68% on volume of 854,652 shares), positioning the stock -15.34% below its 50-day simple moving average ($6.91) and -27.69% below its 200-day simple moving average ($8.09). Across its 52-week range of $5.16 to $13.67, KYTX sits at the 8.1% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.12 to $6.58).

KYTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KYTX stock right now?

Kyverna Therapeutics Inc. (KYTX) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is KYTX's 12-month price target and RQD AI Jury consensus?

KYTX's 12-month base price target is $5.43 (range $4.24 to $14.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KYTX RQD Cockpit KYTX 12M Forecast KYTX Earnings & Move KYTX Dividends & DRIP KYTX Insiders & 13F KYTX Whale Options KYTX Profit Sankey KYTX News & Why